GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Predilife SA (XPAR:ALPRE) » Definitions » Notes Receivable

Predilife (XPAR:ALPRE) Notes Receivable : €0.00 Mil (As of Jun. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Predilife Notes Receivable?

Predilife's Notes Receivable for the quarter that ended in Jun. 2023 was €0.00 Mil.


Predilife Notes Receivable Historical Data

The historical data trend for Predilife's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Predilife Notes Receivable Chart

Predilife Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Notes Receivable
Get a 7-Day Free Trial - - - - -

Predilife Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Predilife Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Predilife Notes Receivable Related Terms

Thank you for viewing the detailed overview of Predilife's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Predilife (XPAR:ALPRE) Business Description

Traded in Other Exchanges
N/A
Address
114 rue Edouard Vaillant Espace Maurice Tubiana, Villejuif, Paris, FRA, 94800
Predilife SA develops solutions of predictive medicine combining proven medical techniques (genetic tests, medical imaging) and mathematical models using a large number of statistical data that could allow each individual to define his risk profile for the occurrence of a large number of serious diseases. The company markets its Mammorisk personalized breast cancer screening solution in Europe and the United States.

Predilife (XPAR:ALPRE) Headlines

No Headlines